Key indicators: single-crystal X-ray study; T = 90 K; mean (C-C) = 0.002 Å; R factor = 0.027; wR factor = 0.069; data-to-parameter ratio = 14.0.
Related literature
Parthenolide (PTL) is a naturally occurring sesquiterpene lactone used in the treatment of fever, migraine headaches, rheumatoid arthritis, and also as an anti-inflammatory agent (Heptinstall et al. (1988) . For the potent anti-tumor and cytotoxic properties of PTL, see: Crooks et al. (2007) . The absolute stereochemistry of the C-11 chiral carbon is typical of such amine adducts of parthenolide, see: Nasim et al. (2007a,b) . For bond-length data, see: Allen et al. (1987) .
Experimental
Crystal data Hydrogen-bond geometry (Å , ). (11R)-13-Dimethylammonio-11,13-dihydro-4,5-epoxycostunolide semifumarate S. Neelakantan, S. Parkin and P. A. Crooks Comment Parthenolide (PTL) isolated from Tanacetum parthenium (commonly referred as feverfew), is a naturally occurring sesquiterpene lactone used in the treatment of fever, migraine headaches, rheumatoid arthritis, and also as an anti-inflammatory agent (Heptinstall et al., 1988) . The PTL molecule and several structurally related analogs have become topics of recent interest because of their potent anti-tumor and cytotoxic properties (Crooks et al., 2007) . Despite promising in vitro activity, this potent natural product has a major limitation which precludes its further development as a therapeutic agent, i.e. its poor water-solubility, thus limiting its potential as a promising clinical agent. The title compound crystallized from water as orthorombic crystals. Bond angles and bond distances within the molecule were quite regular with average normal bond lengths (Allen et al., 1987) . The absolute stereochemistry of the newly formed C-11 chiral carbon was found to be R, which is typical of such amine adducts of parthenolide (Nasim et al., 2007a (Nasim et al., , 2007b . Hydrogen bonding was observed between N1-H and O6 of the carbonyl oxygen of the fumarate moiety and between O4-H and O6 (Table 1 ). The title compound is more water soluble and more biologically potent than the parent compound, in both in vitro and in vivo anti-leukemic activity screens. T he title compound is currently in phase 1 clinical trials.
The title compound (Systematic name: 13-(N,N-dimethyl)-amino-4 α,5 β-epoxy-4,10-dimethyl-6 α-hydroxy-12-oicacid-γ-lactone-germacra-1(10)-ene monofumarate) was synthesized by dissolving PTL (25 mg, 0.1 mmol) in 8 ml of methanol followed by addition of dimethylamine (0.15 mmol, 2.0M solution in methanol). The mixture stirred under ambient conditions for 6 hrs. The crude product was subjected to flash silica gel column chromatography to afford the pure dimethylamino analog free base. The free base was then converted to the fumarate salt by dissolving it in diethyl ether followed by addition of one equivalent of fumaric acid. The white solid that precipitated out of the diethyl ether solution was filtered, washed with diethyl ether and then dried under vacuum. Crystallization of the obtained white solid from water afforded colorless crystals that were suitable for X-ray analysis. 67.1 (5-C), 58.3 (4-C), 49.6 (7-C), 44.9 (11-C), 42.5 (9-C), 38.1 (3-C), 30.9 (8-C), 26.1(2-C), 18.7 (15-C), 18.6 (14-C)p.p.m.
Elemental analysis: calc. for C 21 H 31 NO 7 : C 61.60%, H 7.63%, N 3.42%. Found: C 61.81%, H 7.64%, N 3.47%. 
